Blood products group CSL cited foreign exchange losses, falling royalties from a drop in sales of its cervical cancer and swine-flu vaccines for a $117 million dive in first-half profit. The company's net result fell to $500.21 million, down from $617.39 million last year when windfall sales of Panvax, the Australian developed swine flu treatment, boosted its bottom line. News